Abstract
ObjectiveAfter patent expiry of the bevacizumab originator product, several biosimilars were approved by the European Medicines Agency. In centralised preparation units, product-specific in-use stability data must be considered. Based on...
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have